Healthcare / Drug Manufacturers - Specialty & GenericNasdaqGS
$7.70
-0.11 (-1.41%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $15.6M · quality 58.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
52/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$445M
P/E
22.0x
↑EV/EBITDA
9.7x
↓ROE
7.5%
↑Gross Margin
42.3%
↓Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+11.7%
FCF CAGR
-14.2%
FCF margin
8.7%
FCF / Net income
0.77x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $180.5M · net income $20.2M · FCF $15.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $180.5M | $180.5M | $161.0M | $142.5M | $129.3M |
| Net Income | $20.2M | $20.2M | $14.5M | $8.3M | $-2.3M |
| EBITDA | $39.2M | $39.2M | $27.8M | $22.4M | $10.8M |
| EPS | 0.35 | 0.35 | 0.25 | 0.15 | -0.05 |
| Gross Margin | 42.3% | 42.3% | 43.5% | 38.9% | 36.1% |
| Operating Margin | 14.5% | 14.5% | 12.5% | 7.1% | 3.5% |
| Net Margin | 11.2% | 11.2% | 9.0% | 5.8% | -1.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.04 | 0.04 | 0.04 | 0.04 | 0.12 |
| Current Ratio | 3.33 | 3.33 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $15.6M | $15.6M | $36.9M | $-1.5M | $24.8M |
| Returns | |||||
| ROE | 7.5% | 7.5% | 5.6% | 3.4% | -1.3% |
| Valuation | |||||
| P/E | 22.00 | 22.00 | 25.80 | 39.67 | — |
| EV/EBITDA | 9.69 | 9.69 | 11.00 | 12.15 | 18.06 |
| P/B | 1.65 | 1.65 | 1.44 | 1.31 | 1.19 |
| Growth & Yield | |||||
| Revenue Growth | 12.1% | 12.1% | 12.9% | 10.2% | — |
| EPS Growth | 40.0% | 40.0% | 66.7% | 400.0% | — |
| Dividend Yield | 3.3% | 3.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
25.0%
EPS terminal req.
$0.68
Spread vs growth
15.0%
5Y implied EPS CAGR
18.8%
EPS terminal req.
$0.83
Spread vs growth
21.2%
10Y implied EPS CAGR
14.3%
EPS terminal req.
$1.33
Spread vs growth
25.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+15.7%
Start / end P/E
27.4x → 22.0x
EPS bridge
0.25 → 0.35
Residual
-7.9%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.